Global life sciences industry is experiencing a period of extraordinary transformation. Fuelled by breakthroughs in biotechnology, data science, and artificial intelligence (AI), it is moving from a product-centric to a patient-and data-driven ecosystem.
In fact, it was the Covid-19 phase that accelerated innovation cycles, and companies are now investing heavily in precision medicine, digital therapeutics, and advanced manufacturing, said Michael Schmidt, partner & member of the executive board, Tenthpin, a global management and consultant company focused on life sciences.
Across the world, collaboration between pharmaceutical companies, biotech start-ups, and technology firms is reshaping research, clinical trials, and patient engagement. The focus has shifted toward real-world evidence, AI-powered analytics, and cloud-enabled platforms that connect laboratories, regulators, and caregivers in real time. As innovation quickens, the industry faces the dual challenge of scaling new technologies while staying compliant, sustainable, and patient- focused, he added.
As innovation surges, the life sciences sector faces its own set of disruptions. Once defined by predictable models, it is now contending with rapid digital transformation, supply chain volatility, and shifting investor expectations. To stay competitive, companies must build resilient, transparent, and data-driven ecosystems that can adapt swiftly and integrate seamlessly with partners while managing environmental and social risks. The rise of personalized, patient-centric models is reshaping treatment delivery. Real-world data and AI are driving clinical trial efficiency and innovation, while resource optimization ensures agility and cost control, Schmidt told Pharmabiz in an email.
Investors now favour de-risked biotech ventures with clear acceleration pathways. Meanwhile, the relentless pace of digital change demands strategic technology roadmaps and cross-system interoperability. To thrive, life sciences companies must strengthen their core capabilities in agility, collaboration, and intelligent decision-making, he said.
India has emerged as a powerhouse in life sciences innovation, blending scientific excellence with digital capability. From established pharma leaders to biotech start-ups, Indian firms are driving affordable global healthcare solutions. Our teams combine deep domain knowledge, strong communication, and problem-solving agility—making India a natural hub for world-class delivery. For Tenthpin, India is not just a resource centre, it is a strategic innovation engine. The Indian delivery teams lead global initiatives in AI, cloud, and Life Sciences solutions, ensuring projects are executed with precision, reliability, and speed. “They don’t just deliver. They co- innovate,” said Schmidt.
Through its subsidiary Tenthpin Solutions, the company has become SAP’s #1 Life Sciences Innovation Partner and winner of the 2025 SAP Pinnacle Award for Partner Industry Innovation. Its collaborations with SAP and global leaders have produced key solutions like: SAP Cell & Gene Treatment Orchestration (CGTO), SAP Batch Release Hub (BRH) and SAP Intelligent Clinical Supply Management (ICSM). Additionally, proprietary tools such as T/IQS (Tenthpin Quality Suite) and T/TOP address quality management, certification, and personalized medicine orchestration.
Partnering with 16 of the world’s top 20 pharma companies, Tenthpin combines regulatory expertise with digital innovation. Its AI Lab in Hyderabad and Life Sciences Cloud Solutions Centre are building next-generation products that help clients enhance compliance, optimize operations, and accelerate innovation—turning disruption into opportunity, said Schmidt. |